多发性硬化症:NLRP3炎症体,气皮素D,以及治疗方法
Amie Brint1,2, Seth Greene3, Alyssa R Fennig-Victor3
1Chemistry Department, University of Arkansas at Little Rock, Little Rock, AR, USA.
Annals of translational medicine
|August 9, 2024
概括
本综述探讨了NLRP3炎症酶和热如何导致多发性硬化症 (MS) 炎症,并确定了疾病管理的治疗点.
科学领域:
- 神经免疫学 神经免疫学
- 细胞生物学 细胞生物学
- 病理生理学 病理生理学
背景情况:
- 多发性硬化症 (MS) 是一种慢性,神经炎症性疾病,影响中枢神经系统.
- 炎症是MS病理学的关键驱动因素,需要对其调节机制进行研究.
- 含有核酸结合的寡合化域 (NOD),含有丰富的白素重复域 (LRR) 和蛋白域 (PYD) 的蛋白3 (NLRP3) 是炎症的关键细胞传感器.
研究的目的:
- 审查NLRP3炎症酶激活和 pyroptosis在MS病变发生中的作用.
- 为了识别MS治疗的pyroptotic途径内的潜在的治疗点.
- 在MS的背景下,阐明NLRP3炎症酶,卡斯巴酶1,气体皮质蛋白D (GsdmD) 和烧之间的联系.
主要方法:
- 文献综述侧重于MS炎症的细胞和分子机制.
- 分析NLRP3炎症酶路径,包括其激活和下游效应因子.
- 检查热致死,特别是GsdmD在神经炎症中的作用.
主要成果:
- NLRP3炎症酶激活导致caspase 1和GsdmD激活,诱导热.
- 烧会加剧神经炎症,对多发性硬化病理有显著的贡献.
- 在NLRP3炎症酶 - 炎症酶轴是MS进展的关键途径.
结论:
- 准NLRP3炎症和 pyroptotic通道为MS提供了一个有前途的治疗策略.
- 抑制这种炎症级联中的关键步骤可以减轻疾病的进展并缓解患者的症状.
- 了解这些机制对于开发治疗多发性硬化症的新方法至关重要.
关键词:
热灭菌的发生.气体皮质 D (GsdmD) 是一种气体皮质.介质蛋白-1β (IL-1β) 是一种蛋白质.多发性硬化症 (MS) 是一种疾病.核酸结合的寡合化域,含有蛋白3 (NLRP3) 的氨酸丰富的重复和蛋白域.更多相关视频
09:04Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
20.9K
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.2K
相关概念视频
01:24T Cell Types and Functions
966
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
966
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
124
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
124
01:29Inflammatory Bowel Disease IV: Pharmacological Management
124
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
124